ChEMBL Tour 2014 - The Netherlands, Belgium, and Luxembourg

Last year Louisa Bellis toured the UK to present on SMSdrug.net and ChEMBL. The tour was well received and a large number of people that had not heard of ChEMBL were introduced to ChEMBL.

Following the success of the previous tour, Gerard van Westen (EMBL –EBI) is going to be doing a 2014 ChEMBL tour. This year’s tour will be going to the BeNeLux. For dates and locations see below. Please feel free to attend and meet up / chat on ChEMBL, contactable via email on gerardvw [at] ebi.ac.uk

Current dates are as follows:

19th of May – Maastricht University
Host: Egon Willighagen
Time: 12.00-17.00
ChEMBL + Allosteric modulators

20th of May – Maastricht University
Host: Jos Kleinjans
Time: 09.00 - 11.30
ChEMBL + Advanced ChEMBL

20th of May – KU Leuven
Host: Pieter Annaert
Time: 14.00 -17.00
ChEMBL

21th of May – KU Leuven
Host: Piet herdewyn
Time: 09.00 -10.00
ChEMBL

21th of May – University of Luxembourg
Host: Reinhard Schneider
Time: 13.00 - 17.00
ChEMBL + Advanced ChEMBL

22nd of May – Universiteit Antwerpen
Host: Koen Augusteyns
Time: 15.00 - 17.00
ChEMBL

26th of May – VU University Amsterdam & Universiteit van Amsterdam
Hosts: Chris de Graaf & Willem Stiekema
Time: 10.00 - 15.00
ChEMBL + Allosteric modulators

28th of May – University of Groningen
Host: Alexander Domling
Time: 14.00 - 17.00
ChEMBL + Advanced ChEMBL

6th of June – Utrecht University
Host: Roland Pieters
Time: 09.00 - 12.00
ChEMBL

6th of June – Universiteit Leiden
Host: Ad IJzerman
Time: 15.30 - 17.00
ChEMBL

17th of June – Erasmus Medical Centre, Rotterdam
Host: Roland Kanaar
Time: 14.00 - 17.00
ChEMBL

18th of June – Radboud University Nijmegen
Host: Tina Ritschel
Time: 13.30 - 15.00
ChEMBL + Allosteric modulators

Comments

Andy said…

I wish you a good trip, Gerard, and may you further increase the fame and glory of ChEMBL :-)! All the best, Andreas

27 May 2014 at 11:52

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and here for a reminder of SureChEMBL is and what it does. This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for local (behind the

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

The ChEMBL-og

Search This Blog